8.33
+1.61(+23.96%)
Currency In USD
| Previous Close | 6.72 |
| Open | 6.82 |
| Day High | 8.47 |
| Day Low | 6.77 |
| 52-Week High | 10.08 |
| 52-Week Low | 1.1 |
| Volume | 6M |
| Average Volume | 1.26M |
| Market Cap | 302.4M |
| PE | -4.65 |
| EPS | -1.79 |
| Moving Average 50 Days | 6.58 |
| Moving Average 200 Days | 4.4 |
| Change | 1.61 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $473.56 as of January 08, 2026 at a share price of $8.33. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 3 years ago, it would be worth $1,884.62 as of January 08, 2026 at a share price of $8.33.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
GlobeNewswire Inc.
Yesterday at 9:00 PM GMT
- Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
GlobeNewswire Inc.
Dec 23, 2025 1:00 PM GMT
NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and liv
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
GlobeNewswire Inc.
Dec 17, 2025 9:05 PM GMT
– End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebim